In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.
Search results for: physical function
A High HAQ at Baseline in Early RA Is a Bad Sign
In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.
Risankizumab May Improve Symptoms of PsA
Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.
A Pandemic of Psychological Distress Is Upon Us
It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…
Tofacitinib Promising for Adults with AS
According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).
Studies Examine Peripheral Nervous System Disease in Lupus Patients
Although systemic lupus erythematosus (SLE) affects both the central nervous system (CNS) and peripheral nervous system (PNS), past research has primarily focused on how lupus affects the CNS. Now, an international, inception cohort study, “Peripheral Nervous System Disease in Systemic Lupus Erythematosus,” published in Arthritis & Rheumatology, has examined different types of PNS disease to…
Rheumatology Health Educators Educate & Empower Patients
As a health educator at Integrative Rheumatology, a private practice in Charlotte, N.C., Latisha Williams, MPH, CHES, CHC, works with patients to teach them how to better manage their disease. In the two-and-a-half years that Ms. Williams has worked at Integrative Rheumatology, she’s answered countless questions about exercise, nutrition and complementary therapies, among other topics. “Patients…
Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…
FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution
In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.
Guselkumab Approved for PsA
Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 76
- Next Page »